NDA 11045, held by Medpointe Pharm Hlc. Estrogens, Conjugated; Meprobamate.
As of Nov 13, 2026, NDA 11045 (Milprem-400, Milprem-200), held by Medpointe Pharm Hlc, was not approved, with 0 approved supplements and 0 published complete response letters.
| Milprem-4000.45MG;400MG · tablet;oral | Estrogens, Conjugated; Meprobamate | Discontinued |
| Milprem-2000.45MG;200MG · tablet;oral | Estrogens, Conjugated; Meprobamate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
